A Study found that Diet Drug Acomplia Reduces Fats very much

In a multi-center study in Japan Diet drug Acomplia (rimonabant, online is the way that you can buy it) was found to reduce very much human visceral fat — the dangerous abdominal fat –,that was announced of Sanofi-Aventis on Sept. 18th.A report on the study was presented at
this year meeting of the European Association for the Study of Diabetes and it talks about the first direct evidence of the way that rimonabant (Acomplia / Zimulti which can be found online) is decreasing the metabolically active fat.That refeares to the fat which surrounds some vital organ as the pancreas and liver.

Researchers reported that the visceral fat area was more  reduced in the study, in 526 obese Japanese participants that were taking the customary 20 mg rimonabant dosage (-40.6cm2) than for those taking a placebo (-20.3cm2).

In the human body exist a couple of adipose tissue, which are characterised by differences:anatomical and metabolic.

The subcutaneous fat is located directly under the skin and contains insulin-sensitive adipocytes (fat cells)very small , while the visceral fat (inter-abdominal adipose tissue),that surrounds the abdominal organs , contains large adipocytes that are insulin-resistant.

Visceral fat in excess, present in patients with abdominal obesity, goes to metabolic imbalance, such as lipid disorders, resistance to insulin and type 2 diabetes, which eventually will lead to cardio-metabolic disease.

So the study shows that Acomplia(rimonamant can be bought online) is very good for the human body.

Approximately one person in 10 taking diet drug Acomplia (rimonabant) experiences psychiatric side effects and about one person in 100 experiences suicidal thoughts, according to U.K. regulators.

Of some 41,000 patients treated with rimonabant since it was launched in the U.K. in June 2006, 364 “psychiatric reactions have been reported,” the Department of Health’s Medicines and Healthcare Products Regulatory Agency (MHRA) said on July 19th.

“Amongst these, there have been 48 reports of depression, 16 reports of suicidal thoughts and one report of self-injury,” the regulatory agency said.

The MHRA said evidence suggested one person in 10 taking Acomplia may develop psychiatric side effects, and “approximately one patient in every 100 may experience suicidal thoughts.”

The MHRA advised: “If you start to experience symptoms of depression while taking Acomplia, or if you are currently being treated with antidepressants, consult your doctor.

“If you have had depression in the past but feel well on Acomplia, you should continue treatment with Acomplia and discuss your treatment with your doctor at your next routine appointment.”

The European Medicines Agency, however, took a more aggressive approach, deciding that Acomplia can remain on the market but with tougher warnings against its use by persons with major depression or anyone on an antidepressant.

The EMEA’s Committee for Medicinal Products for Human Use (CHMP) said “too many patients are taking Acomplia at the same time as antidepressants, even though Acomplia is not recommended for use in patients also taking antidepressants.”

While the CHMP said “Acomplia must no longer be used in these patients,” it concluded “that the benefits of Acomplia continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.”

The European Medicines Agency (EMEA) recommended contraindicating Acomplia (rimonabant) from sanofi-aventis, in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects. Doctors in the EU have already been warned about this since June 2006 but the Agency’s Committee for Medicinal Products for Human Use (CHMP) has now recommended upgrading this warning.